Coherus Oncology (CHRS) Gains from Investment Securities (2013 - 2019)
Coherus Oncology (CHRS) posted Gains from Investment Securities of $43000.0 for Q4 2019, up 760.0% sequentially from $5000.0 in Q3 2019, and up 530.0% YoY from $6825.4 in Q4 2018.
Coherus Oncology (CHRS) Gains from Investment Securities (2013 - 2019) Analysis & Trends
Coherus Oncology has reported Gains from Investment Securities for 7 years, with the latest figure at $43000.0 in Q4 2019.
- Quarterly Gains from Investment Securities rose 530.0% year-over-year to $43000.0 in Q4 2019, while the trailing twelve-month figure through Dec 2019 was $52000.0 (down 98.56% YoY) and the FY2019 annual result came in at $42000.0, up 101.3% from the prior year.
- Gains from Investment Securities climbed to $43000.0 in Q4 2019 per CHRS's latest filing, from $5000.0 in the prior quarter.
- Over five years, Gains from Investment Securities peaked at $5.1 million in Q2 2016 and troughed at -$1.6 million in Q3 2016.
- A 5-year average of $861789.5 and a median of $185000.0 in 2015 frame the typical range for Gains from Investment Securities.
- The widest YoY moves for Gains from Investment Securities: up 7746.15% in 2016, down 1085.19% in 2016.
- Over 5 years, Gains from Investment Securities stood at $185000.0 in 2015, then soared by 202.7% to $560000.0 in 2016, then declined by 5.36% to $530000.0 in 2017, then slumped by 101.89% to -$10000.0 in 2018, then jumped by 530.0% to $43000.0 in 2019.
- According to Business Quant data, Gains from Investment Securities over the past three periods registered $43000.0, $5000.0, and $4000.0 for Q4 2019, Q3 2019, and Q1 2019 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Coherus Oncology | 221.39 Mn | 116.08 Mn | 10.07 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2019 | 43,000.00 |
| Dec 31, 2019 | 43,000.00 |
| Sep 30, 2019 | 5,000.00 |
| Sep 30, 2019 | 5,000.00 |
| Mar 31, 2019 | 4,000.00 |
| Mar 31, 2019 | 4,000.00 |
| Dec 31, 2018 | -10,000.00 |
| Dec 31, 2018 | -10,000.00 |
| Sep 30, 2018 | 25,000.00 |
| Sep 30, 2018 | 25,000.00 |
| Jun 30, 2018 | 3.40 Mn |
| Jun 30, 2018 | 3.40 Mn |
| Mar 31, 2018 | 208,000.00 |
| Mar 31, 2018 | 208,000.00 |
| Dec 31, 2017 | 530,000.00 |
| Dec 31, 2017 | 530,000.00 |
| Sep 30, 2017 | -300,000.00 |
| Sep 30, 2017 | -300,000.00 |
| Jun 30, 2017 | 3.50 Mn |
| Jun 30, 2017 | 3.50 Mn |